- Home
- BKR vs ARGX Comparison
BKR vs ARGX Comparison
Compare BKR & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKR
- ARGX
- Stock Information
- Founded
- BKR 2016
- ARGX 2008
- Country
- BKR United States
- ARGX Netherlands
- Employees
- BKR N/A
- ARGX N/A
- Industry
- BKR Metal Fabrications
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BKR Industrials
- ARGX Health Care
- Exchange
- BKR Nasdaq
- ARGX Nasdaq
- Market Cap
- BKR 43.5B
- ARGX 37.3B
- IPO Year
- BKR N/A
- ARGX 2017
- Fundamental
- Price
- BKR $40.32
- ARGX $623.82
- Analyst Decision
- BKR Strong Buy
- ARGX Strong Buy
- Analyst Count
- BKR 19
- ARGX 20
- Target Price
- BKR $46.47
- ARGX $634.50
- AVG Volume (30 Days)
- BKR 6.5M
- ARGX 290.3K
- Earning Date
- BKR 01-30-2025
- ARGX 10-31-2024
- Dividend Yield
- BKR 2.08%
- ARGX N/A
- EPS Growth
- BKR 33.57
- ARGX N/A
- EPS
- BKR 2.23
- ARGX N/A
- Revenue
- BKR $27,300,000,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- BKR $9.26
- ARGX $61.99
- Revenue Next Year
- BKR $2.25
- ARGX $42.48
- P/E Ratio
- BKR $18.09
- ARGX N/A
- Revenue Growth
- BKR 11.08
- ARGX 85.56
- 52 Week Low
- BKR $28.32
- ARGX $349.86
- 52 Week High
- BKR $45.17
- ARGX $644.97
- Technical
- Relative Strength Index (RSI)
- BKR 40.45
- ARGX 58.04
- Support Level
- BKR $40.35
- ARGX $613.95
- Resistance Level
- BKR $41.83
- ARGX $644.97
- Average True Range (ATR)
- BKR 1.09
- ARGX 14.33
- MACD
- BKR -0.44
- ARGX -0.42
- Stochastic Oscillator
- BKR 19.38
- ARGX 50.28
About BKR Baker Hughes Company
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. It maintains modest exposure to offshore oil and gas production. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with a high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.